3Colhoun HM, Betteridge D J, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: ananalysis from the Collaborative Atorvastatin Diabetes Study (CARDS) [J]. Am J Kidney Dis,2009;54(5) :810-9.
6Abdin AA, Hassanien MA, Ibrahim EA,et al. Modulating effect of atorvas- tatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy[J]. J Diabetes Complications,2010;24(5) :325-33.
3[2]Brancati FL,Cusumano AM.Epidemiology and prevention of diabetic nephropathy[J].Curr Opin Nephrol Hypertens,1995;4(3):223-229
4[3]Breyer JA.Diabetic nephropathy in insulin-dependent patients[J].Am J Kindey Dis,1992;20:533-547
5[4]Hostetter TH.Early renal function in diabetes and risk factors for development of diabetic nephropathy.in:Jacobson HR,Striker CE,Klahr S,eds.The principles and practice of nephrology[M].Philadelphia BC Decker,1991:460-462
6[5]Mongensen CE.Microalbuminuria as a predictor of clinical diabetic nephropathy[J].Kidney Int,1987;31(2):673-689
7[6]Viberti GC,Wiseman M.The kidney in diabetes:Significance of early abnormalities[J].Clin Endocrinol Metab,1986;9:85-92
8[7]Nielsen S,Schmitz A,Mogensen CE.Rate of progression of nephropathy in normal and microalbuminurial type Ⅱ diabetic patients.Diabetologia[J],1991;34(suppl 2):A144
9[8]Schmitz A.Microalbuminuria and mortality in non-insulin-depen dent diabetes.In:Mogensen CE,ed.The Kidney and Hypertension in Diabetesc[M].Boston:Martinus Nijhoff Publishing,1988:6570
10[9]Christensen CK,Mogensen CE.The course of incipients nephropathy:studies on albumin excretion and blood pressure[J].Diabetic Med,1985;2:97-102
7Kouroumichakis I, Papanas N, Zarogoulidis P, et al. Fibrates:therapeutic potential for diabetic nephropathy? European Journal of Internal Medicine,2012,23 (4) : 309 - 316.
8Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of ator- vastatin on kidney outcomes and cardiovascular disease in pa- tients with diabetes: an analysis from the Collaborative Atorvas- tatin Diabetes Study (CARDS). Am J Kidney Dis ,2009,54 (5) : 810 -819.
9Fernandez - Ju6rez G, Barrio V, de Vinuesa SG, et al. Dual blockade of the renin - angiotensin system in the progression of renal disease:the need for more clinical trials. J Am Soc Neph- rol,2006,17(3) :S250 - S425.
10Rosario RF, Prabhakar S. Lipids and diabetic nephropathy. Curt Diab Rep,2006,6(6) :455 -462.
